Cosmos Health Introduces Guidance; Expects to Achieve Over $180M in Gross Annual Revenue and EBITDA in Excess of $20M by 2026; Recaps Significant Events Reported So Far in 2023Accesswire • 09/12/23
Cosmos Health Reports Q2 2023 Financial Results; Adjusted Net Income Increases by 3550% to Surpass $3 Million for H1 2023 vs $(0.09) Million H1 2022; Book Value per Share Exceeds $4.04Accesswire • 08/15/23
Cosmos Health Continues to Expand Mediterranation Brand, Welcomes Eleonas and Olympus Mons; Boosts Exports and Secures Purchase Orders, Including from Leading Multinational Health Food ChainAccesswire • 08/02/23
Cosmos Health Provides Update on Recent Developments, Maintains Strong Financial Position, Reaffirms Commitment to Growth, and Highlights CEO's Continued Investment Now Exceeds $15 MillionAccesswire • 07/25/23
Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private PlacementAccesswire • 07/21/23
Cosmos Health Inc. Announces Pricing of $5.25 Million Registered Direct Offering and Concurrent Private PlacementAccesswire • 07/20/23
Cosmos Health Successfully Completes Acquisition of Cana Laboratories; Anticipates to Record a Substantial Gain on Bargain PurchaseAccesswire • 07/06/23
Cosmos Health Launches Chios Island, the Latest Addition to Its Mediterranation Premium Line of SupplementsAccesswire • 06/29/23
Cosmos Health Successfully Completes Second Phase of CCX0722 Development, an Innovative Product for Obesity and Weight Management: Significant Step in Bringing Product to the Multi-Billion-Dollar MarketAccesswire • 06/21/23
Cosmos Health Successfully Closes Acquisition of Assets from I. Bikas GP; Annual Revenue Projected to Grow by over $10 MillionAccesswire • 06/16/23
Cosmos Health Expands Premium Nutritional Supplements Line Mediterranation with the Launch of Terra CretaAccesswire • 06/13/23
Cosmos Health Enters into Binding Letter of Intent for the Acquisition of Docpharm GmbH., an Established German Pharmaceutical Distributor; Expected to Boost Our Annual Revenue by Approximately €32M, or 70%, by the End of 2025 vs FY 2022.Accesswire • 05/25/23
Cosmos Health Reports First Quarter 2023 Financial Results; Delivers Positive Adjusted EBITDA and Significant Increase in Adjusted Net IncomeAccesswire • 05/17/23
Cosmos Health Enters Final Phase for the Acquisition of Cana Laboratories Following Conclusion of Stock Purchase AgreementAccesswire • 05/08/23
Cosmos Health Advances Its Strategic Plan; Acquires Distressed Property Housing Operations of CosmoFarm, Expected to Generate Substantial Value for ShareholdersAccesswire • 05/03/23
Cosmos Health Ends 2022 with Transformed Balance Sheet and Achieves Positive Adjusted EBITDA for the Fiscal Year 2022Accesswire • 04/13/23
Cosmos Health Inc. to Participate in The Economist Annual New York-Eastern Mediterranean Business Summit on July 10th, 2023, with CEO Mr. Greg Siokas Delivering a SpeechAccesswire • 04/05/23
Cosmos Health Inc. Enters U.S. Telehealth Space with Successful Acquisition of ZipDoctor, Inc.Accesswire • 04/03/23
Cosmos Health Inc.'s UK Subsidiary Decahedron Ltd. Named Pharmaceutical Wholesaler of the Month in the Latest Issue of Healthcare MattersAccesswire • 03/24/23
Cosmos Health Inc. Enters into a Definitive Agreement to Acquire ZipDoctor, Inc., a Telehealth Company, from American International Holdings Corp.Accesswire • 03/17/23
Cosmos Health Enters into a Material Definitive Agreement with Cana LaboratoriesAccesswire • 03/07/23